Article
Engineering CAR T Cells for Hepatocellular Carcinoma Recurrence after Liver Transplantation
2026-07-05
Abstract excerpt
<h4>Background & Aims</h4> Liver transplantation improves outcomes in hepatocellular carcinoma (HCC), yet treatment options for patients with tumor recurrence remain limited to tyrosine kinase inhibitors. Glypican-3 (GPC3)-targeted CAR T cells offer a tumor-directed immune-based therapeutic strategy, but their efficacy may be limited by post-transplant immunosuppression. We developed a CAR T cell platform combini...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 58420a6a-3ff1-5cc8-8806-a461877437e8
- DOI
- 10.64898/2026.06.30.735569
